diosurgery is presented in Table 1. The tumor volumes varied from 0.42 to 25 cm  3 (median 3 cm   3   ) , and the radiation dose to the tumor margin varied from 9.6 to 22.5 Gy (median dose 15 Gy).
The diagnosis of pilocytic astrocytoma was confirmed with the aid of stereotactic biopsy in 12 patients, open biopsy in five, partial resection in eight, and near-total resection in 12. Analysis of tumor control was stratified according to whether the tumor was cystic, solid and circumscribed, or multifocal (diffuse). In total, 25 patients harbored tumors that were solid and circumscribed (Table 1 ). In the group of patients treated using radiosurgery in the adjuvant setting, 12 harbored tumors that were solid and circumscribed and five harbored cystic tumors. Among patients with recurrent tumors treated with radiosurgery, 13 harbored solid and circumscribed tumors, three had cystic tumors, and four had multifocal tumors. In all patients, treatment management included at least one CT-or MR imaging-guided stereotactic radiosurgery procedure performed between 1987 and 2000. All patients in this study presented for radiosurgery after initial biopsy or attempted surgical resection. Gamma knife surgery was performed as an adjunct to stereotactic biopsy, stereotactic cyst aspiration, open biopsy, or surgical resection, or as treatment of recurrent tumors after surgical resection.
Radiosurgery began with rigid fixation of an imagingcompatible Leksell stereotactic frame (model G; Elekta Instruments, Atlanta, GA) to the patient's head. Regional anesthetic scalp infiltration (5% Marcaine and 1% Xylocaine buffered with sodium bicarbonate) and mild sedation were used. General anesthesia was induced in children younger than 12 years of age. Stereotactic CT scanning was performed for target localization and planning before 1993, after which we used MR imaging because of its better image resolution, superior tissue contrast, and virtually artifactfree images. After 1993, CT scanning was undertaken only if metal implants in the patient's body contraindicated the use of MR imaging. High-resolution gadolinium-enhanced T 1 -weighted sagittal scout MR images were first obtained to localize the area of interest. To define the radiosurgery target volume, multiplanar volume-acquisition contrast-enhanced MR imaging (divided into 28-60 axial slices of 1-mm thickness) was performed. All tumors enhanced on CT or MR images in response to the addition of a contrast agent. These images were transported via fiberoptic ethernet to a high-speed computer workstation for gamma knife treatment planning. The planning was performed with the aid of axial images supplemented by reformatted coronal and sagittal images. A conformal plan was assembled using multiple isocenters of different diameters. The treatment volume consisted of the enhancing component of the tumor and the cyst wall if present. After finalizing the plan, a maximum dose to the tumor margin was determined. The treatment isodose, maximum dose, and dose to the tumor margin were decided among a neurosurgeon, a radiation oncologist, and a medical physicist. The dose was selected based on tumor volume, location, and estimated tolerance of nearby critical structures, especially if previous fractionated radiation therapy was administered. Radiosurgery was performed with a 201-source, 60 Co Leksell gamma knife (model U, model B; Elekta Instruments) by positioning the target serially at x, y, and z coordinates of each isocenter. All patients received a dose of 10 to 40 mg of methylprednisolone at the conclusion of the procedure. The stereotactic frame was removed immediately afterward, and the patients were discharged within the next 6 to 18 hours.
All patients underwent serial follow-up imaging (usually MR imaging) sessions, which were requested at 3-, 6-, 12-, and 24-month intervals if no tumor growth was noted. In patients in whom neurological deterioration was observed, interval scans were obtained. If there was no appreciable change in tumor size, subsequent MR images were requested at 1-year intervals. Those patients who lived a long distance from Pittsburgh were evaluated by their referring physician, who then forwarded imaging and clinical data to the Center for Image-Guided Neurosurgery at the University of Pittsburgh. Patients or their families were also contacted by telephone to optimize follow-up review.
Morbidity and survival data (from both the time of diagnosis and the time of radiosurgery) were assessed. Timing of treatment (whether the tumor was treated using stereotactic radiosurgery in an adjuvant fashion or for lesion recurrence) was analyzed. The effects of tumor location, target volume, and the presence or absence of cystic change were evaluated. The influence of a circumscribed, as op- posed to a multifocal (diffuse), tumor on survival time was also assessed. Actuarial survival rates were calculated using the Kaplan-Meier method. Univariate analysis of factors affecting survival was performed using the log-rank test and multivariate analysis was performed using the Cox proportional hazards model.
Results

Clinical Outcomes
Thirty-three (89%) of 37 patients are alive at a median length of follow up of 28 months after radiosurgery (range 3-92 months) and 59 months after diagnosis (range 2-186 months), providing a 7-year actuarial survival rate of 76% (Fig. 1) . The median length of survival has not yet been reached. Procedure-related permanent morbidity or mortality did not occur in this series. All surviving patients in the study have Karnofsky scores ranging from 80 to 100 as of the last follow-up examination. Three patients died of local tumor progression 23, 72, and 115 months after diagnosis, respectively, and 7, 71, and 29 months after the time of GKS. One of these patients required placement of a VP shunt to relieve hydrocephalus after radiosurgery and remained free from symptoms for 66 months before tumor progression occurred. The patient died shortly thereafter. Another patient in the series died of respiratory failure caused by pneumonia unrelated to brain tumor.
Adverse Effects of Radiation
Two patients experienced temporary worsening of their neurological conditions after radiosurgery. Magnetic resonance imaging revealed increased contrast enhancement of tumor associated with T 2 sequence changes in surrounding brain. One patient displayed deterioration in speech 6 months after radiosurgery and 12 months after undergoing fractionated radiation therapy. At another institution this patient was believed to be experiencing tumor recurrence and was treated with steroid medications and a new chemotherapeutic regimen (ifosfamide, carboplatin, and etoposide). We believe the imaging changes associated with the patient's clinical deterioration were due to radiation effect and were not indicative of tumor recurrence. On follow-up imaging 24 months after radiosurgery, there was decreased enhancement and T 2 change associated with the tumor. This patient displayed no expressive aphasia at the last clinical follow-up examination. The other patient displayed a slight worsening of his hemiparesis 7 months after radiosurgery. The patient eventually experienced improvement of hemiparesis and a greater than 50% reduction in the size of his tumor 28 months after radiosurgery.
Imaging Results
Follow-up imaging studies demonstrated tumor control in 25 (68%) of 37 patients at a median of 25 months. Complete resolution was identified in 10 patients and a greater than 50% reduction in tumor volume in eight patients (median duration of follow up in these groups was 25 and 28 months, respectively). In seven patients the appearance of the tumor remained unchanged after radiosurgery (median follow up 20.5 months). In 12 patients (32%) delayed tumor growth was demonstrated at a median of 23 months. In five of these patients there was an increase in cyst size only (Tables 2 and 3).
Tumor control was achieved in 13 (76%) of 17 patients who were treated with radiosurgery in an adjuvant fashion and in 12 (60%) of 20 patients with recurrent tumors (median follow up in these groups was 28 and 27 months, respectively). In the adjuvant setting, complete resolution of the tumor was confirmed in five patients, a greater than 50% reduction in tumor size in four patients, and no change in tumor size in four patients. In four other patients (24%) local tumor progression was identified on follow-up images. In two patients there was an increase in cyst size only. One patient died of local tumor progression 71 months after radiosurgery. Among patients with recurrent tumors treated using radiosurgery, complete resolution was documented in five patients, a greater than 50% reduction in tumor size in four patients, and no change in tumor size in three patients. In eight patients (40%) local tumor progression was noted on follow-up images. In three of these patients there was an increase in cyst size only. Two patients died of local tumor progression 7 and 29 months, respectively, after radiosurgery.
Tumor control was achieved in 21 (84%) of 25 patients with solid, circumscribed tumors and was verified with the aid of images obtained after radiosurgery (median follow up 30 months). In eight patients complete resolution of tumor was demonstrated on follow-up images. In seven patients a greater than 50% reduction in tumor size was observed. In six patients there was no change in tumor size, whereas in four patients (16%) local tumor progression was FIG. 1. Kaplan-Meier graphs showing disease-specific survival (left) and overall tumor control (center) in patients treated with radiosurgery for pilocytic astrocytomas, as well as overall tumor control in patients treated using radiosurgery in an adjuvant fashion and those treated for recurrent pilocytic astrocytomas (right). n = number of patients.
identified on follow-up images. Local tumor progression was exhibited in three of four patients who harbored multifocal tumors according to follow-up imaging data (median follow up 22 months); two of these patients died. In five of eight patients with cystic tumors there was an increase only in cyst size after radiosurgery (median follow up 26 months).
Pilocytic Astrocytomas Located in the Brainstem
Progressive lesions were located in the brainstem in 18 patients. In 12 (67%) of these patients the lesions were solid, circumscribed tumors, in two patients (11%) they were cystic, and in four patients (22%) they were multifocal. Tumor control was achieved in 10 (56%) of 18 patients after radiosurgery (median follow up 29 months). In four patients there was complete resolution, in four there was a decrease in tumor size, and in two patients the size of the tumor was stable after radiosurgery. Follow-up imaging demonstrated tumor progression in eight patients (44%). Two patients underwent additional cytoreductive surgery. Three patients died of local tumor progression.
Nine patients with pilocytic astrocytomas located in the brainstem were treated using radiosurgery in an adjuvant fashion. In six (67%) of these patients tumor control was achieved after radiosurgery and in three (33%) there was evidence of tumor progression on follow-up images. In two of the latter patients there was an increase in cyst size only. Nine patients were treated using radiosurgery for recurrent pilocytic astrocytomas located in the brainstem. In four patients (44%) tumor control was achieved after radiosurgery and in five patients (56%) tumor progression was evident on follow-up images.
Biopsy Followed By Radiosurgery
In this series, 11 patients underwent biopsy of their tumor, which had been performed openly (three patients) or by using stereotactic technique (eight patients) before they underwent radiosurgery (Fig. 2) . The location of these tumors included the brainstem in six patients, the parietal lobe (perirolandic) in two patients, and the thalamus, temporal lobe, and third ventricle in one patient each. These patients had not undergone previous resection of tumor. Only one patient underwent any additional therapy after radiosurgery. The patient received fractionated radiation therapy 9 months following radiosurgery at another institution because of worsening hemiparesis. In nine (82%) of 11 patients tumor control was achieved by the last follow-up examination (median follow up 26 months). In four patients complete resolution of tumor was confirmed on follow-up images. Follow-up images demonstrated a greater than 50% reduction of tumor size in two patients and stable tumor size in three patients. Tumor progression was identified in two patients (18%). One patient died of local tumor progression. fluencing outcomes after radiosurgery such as patient age and sex, location and volume of tumor, radiosurgical dose, prior surgery, timing of radiosurgery (adjuvant compared with recurrent treatment), previous fractionated radiation therapy, well-circumscribed or multifocal nature of tumor, or cystic appearance. Factors predicting worse outcomes include multifocal tumors, failed fractionated radiation therapy, older patient age, and lower radiosurgical tumor dose (Table 4) .
Factors Influencing Outcomes
Treatment After Radiosurgery
Among the 12 patients in whom there was delayed tumor growth, four required additional cytoreductive surgery. In five patients there was only an increase in tumor cyst size requiring cyst drainage. One patient underwent repeated GKS. Other treatments following radiosurgery included stereotactic cyst evacuation in three patients, stereotactic intracavitary irradiation in four, chemotherapy in two, and fractionated radiation therapy and VP shunt placement in one patient each.
Stereotactic Cyst Evacuation
Six patients required stereotactic cyst evacuation. In three patients stereotactic cyst aspiration was performed within 1 month before radiosurgery. Four patients underwent cyst aspiration after radiosurgery due to symptomatic cyst enlargement. Two of these patients experienced cyst recurrence requiring repeated cyst aspiration. Among these two patients, one patient required cyst aspiration at the time of radiosurgery and 6 months after radiosurgery due to cyst recurrence. The other patient underwent cyst aspiration within 1 month after radiosurgery and repeated drainage 18 months later. Another patient required placement of a cyst reservoir for multiple cyst aspirations. One patient underwent near-total resection because of tumor progression and another patient continues to have slight cyst enlargement, as demonstrated on follow-up images. Follow-up imaging revealed a stable lesion in an additional patient.
Stereotactic Intracavitary Irradiation
After radiosurgery, stereotactic intracavitary irradiation of tumor was performed using phosphorus-32 in four patients. Phosphorus-32 was placed at the time of radiosurgery in another patient. These patients all harbored tumors with enlarging cysts at the time of 32 P implantation, requiring subsequent stereotactic cyst aspiration because there was cyst recurrence. Follow-up imaging demonstrated slight cyst enlargement in one patient, significant regression of tumor in two patients, and a stable lesion in one patient.
Fractionated Radiation Therapy
Ten patients underwent fractionated radiation therapy and were available for a median follow up of 27 months. Nine patients underwent fractionated radiation therapy before radiosurgery. Among these nine patients, tumor biopsy was performed in three, near-total removal of tumor in three, and partial removal of tumor in three before fractionated radiation therapy. Six patients underwent fractionated radiation therapy used in an adjuvant fashion and three patients received fractionated radiation therapy for tumor recurrence. In all these patients recurrent tumors were identified on follow-up images at the time of radiosurgery. After stereotactic radiosurgery, regression in tumor size was identified in five patients, complete resolution of tumor in two patients, and significant regression in tumor size in two patients. There was no change in tumor size in two patients and progression of tumor in three patients. One patient required a second near-total resection, whereas two patients died of tumor progression. One patient received fractionated radiation therapy after radiosurgery at another institution for worsening hemiparesis. Follow-up images revealed a significant decrease in tumor size and clinical evaluation demonstrated improvement in motor strength in that patient.
Chemotherapy Regimen
Two patients received chemotherapy as partial treatment of tumor recurrence. In both cases chemotherapy was given after radiosurgery. One patient received one cycle of carboplatin/vincristine 14 months after radiosurgery. This patient had undergone fractionated radiation therapy and stereotactic cyst aspiration before radiosurgery. Stereotactic radiosurgery was performed within 2 hours after cyst aspiration to capitalize on the reduced target volume. Because of continued cyst enlargement, the patient underwent stereotactic radiation treatment with phosphorus-32 and repeated cyst aspiration after radiosurgery, with a significant decrease in tumor size demonstrated on recent follow-up images. The second patient underwent four cycles of procarbazine/lomustine/vincristine (PCV) and carboplatin/ifosfamide/etoposide 10 months after radiosurgery, as well as temozolomide treatment 27 months after radiosurgery; on the latest follow-up MR image obtained in that case the lesion is stable.
Aggressive Tumors
Nine patients harbored pilocytic tumors that behaved in a very aggressive manner, requiring multiple surgical resections and/or other therapies. Five of these patients required multiple surgical resections before they underwent radiosurgery. Two patients underwent repeated resection after radiosurgery because of tumor progression. According to imaging data, three of nine patients with very aggressive tumors were found to harbor multifocal tumors that progressed after radiosurgery. One patient with a multifocal tumor died of local tumor progression within 24 months after radiosurgery; this patient had undergone two partial resections and fractionated radiation therapy before radiosurgery. Another patient with a multifocal tumor died of local tumor progression 7 months after radiosurgery; this patient had undergone partial resection and fractionated radiation therapy before radiosurgery, and repeated radiosurgery was performed 1 month after the initial session because new tumor growth had been identified. One patient underwent six treatment modalities for a midbrain pilocytic astrocytoma (Fig. 3) . Before undergoing radiosurgery, the patient underwent VP shunt placement, fractionated radiation therapy, and stereotactic cyst aspiration. Due to tumor progression after radiosurgery, the patient underwent stereotactic intracavitary radiation treatment, chemotherapy, and repeated cyst drainage. On the last follow-up image obtained in this patient, a greater than 50% reduction in tumor volume was confirmed. Another patient underwent two resections and fractionated radiation therapy before radiosurgery. This patient subsequently underwent multiple cyst aspirations and stereotactic intracavitary radiation treatment because of cyst enlargement. At the last follow-up examination, a 50% volume reduction in tumor size was found.
Discussion
Pilocytic astrocytoma is the most common brain tumor affecting children. 25 These tumors are usually circumscribed, slow-growing lesions that rarely undergo progression to anaplasia. 22 Whenever possible, symptomatic or progressive pilocytic astrocytomas should be resected completely. 6, 14, 16, 20, 21 Even after partial removal of the tumor, patients with pilocytic astrocytomas can be observed with periodic imaging examinations before any additional surgery or other treatment modalities need to be performed. In some patients, however, pilocytic astrocytomas exhibit a more aggressive course characterized by progressive tumor growth. These patients eventually face poor outcomes if further treatment fails. 10, 32 Tumor progression usually requires repeated operation followed by other treatment modalities.
Treatment Modalities
Surgery. Resection is the mainstay of treatment for pilocytic astrocytomas because these tumors often behave like benign lesions. Complete surgical excision leads to long-term freedom from disease and overall survival in the majority of patients (close to 100%). 9, 12, 17, 18, 33, 35 Gross-total excision, however, is more likely to be accomplished in patients with circumscribed tumors in noneloquent sites such as the cerebellum. The prognosis for patients who undergo subtotal resection (Ͼ 90%) of tumor is thought to be similar to those who undergo complete excision.
1,2 Nevertheless, axial tumors involving midline structures are rarely excised completely or subtotally because of their location. In a review of midline tumors, Hoffman, et al., 19 reported a worse prognosis for patients harboring pilocytic astrocytomas compared with those harboring other low-grade tumors. In their series of 88 children with low-grade astrocytomas, the researchers performed biopsies to confirm that 32 were pilocytic astrocytomas located in the optic chiasm/hypothalamus (25 patients), thalamus (four patients), and medulla (three patients). The rate of recurrence of pilocytic astrocytomas was 62.5%, with a mortality rate of 28.1%.
Radiation Therapy. For those patients in whom total or subtotal resection cannot be safely performed, alternative management strategies have often been recommended. Ra- diation therapy is recommended most often for patients whose tumors are located in critical or deep brain areas. 5, 6, 13, 15, 27, 29, 30 The role of postoperative radiation therapy following partial resection of this tumor remains unclear. 14, 15, 18 Although better disease-free survival has been reported in various series of radiation therapy, the potential long-term adverse effects of radiation therapy in children raise concerns. Adverse effects of cerebral irradiation include memory loss, diminished cognitive abilities, learning disabilities, progressive deterioration in intelligence, impairment of fine-motor and visual-motor skills, and endocrinopathies. 3, 8, 11, 31 Malignant transformation in tumors treated using radiation therapy has also been reported. 4, 7, 10, 11 Moreover, conventional fractionated radiation therapy does not necessarily prevent recurrence. 19 The vulnerability of the immature nervous system to therapeutic doses of radiation has caused significant reluctance on the part of physicians to use conventional fractionated radiation therapy in infants and very young children.
Chemotherapy. Over the past two decades a variety of cytotoxic drugs have been used for newly diagnosed or recurrent low-grade gliomas. There is no consensus on the use of chemotherapy for pilocytic astrocytomas at present. Various reports, however, indicate that chemotherapy permits delay or even avoidance of radiation therapy in patients with low-grade gliomas. 28, 30 Packer and colleagues 28 reviewed the results of combination chemotherapy using carboplatin and vincristine in 78 children who harbored lowgrade tumors. They reported a 77% 3-year progression-free survival rate in 17 patients with pilocytic astrocytomas. Although chemotherapy was relatively well tolerated, five patients in their series had to be excluded from the study as a result of allergic reactions, and one child died due to overwhelming sepsis. These authors also reported occasional delays in treatment caused by prolonged thrombocytopenia or neurotoxicity. Two-and 3-year progression-free survival rates were better in children younger than 5 years (81% and 74%, respectively), compared with those in older children (58% and 39%, respectively). The usefulness of chemotherapy for older children with low-grade gliomas still remains unproved.
Role of Radiosurgery
For brain tumors, the efficacy of conventional fractionated radiation therapy is dependent on the differential biological sensitivity of normal and tumor cells to radiation. Growth kinetics of pilocytic astrocytomas make the radiosensitivity of normal cells and neoplasms very similar. Because of its capability to deliver a high radiation dose to a tumor with a sharp fall off to normal surrounding tissue, radiosurgery is not limited by the differential biological sensitivity of tumor and normal cells. The goal of radiosurgery is to arrest the cell-division capability of target cells, regardless of the individual cell's mitotic activity and radiosensitivity. Radiosurgery also allows for delayed intratumoral vascular obliteration. For the developing nervous system, the opportunity to utilize focused radiation to the lesion represents an attractive treatment alternative that may reduce the potential long-term risks of cognitive or endocrinological dysfunction after fractionated radiation therapy. 24 Ste- reotactic radiosurgery also eliminates the potential systemic toxicity associated with chemotherapy.
Patients with progressive, circumscribed pilocytic astrocytomas located in critical or deep areas of the brain are ideal candidates for radiosurgery. In our series of 37 patients, tumor control was achieved in 25 patients (68%). For patients with solid, circumscribed tumors, the tumor control rate was 84%. Radiosurgery was performed as a part of multimodal therapy in the majority of patients in the series. No permanent complications occurred following radiosurgery, and all 33 patients who are alive remain free from cognitive or endocrine deficits.
In the past we have shown that stereotactic radiosurgery for intraparenchymal brainstem tumors can be performed safely. 23 In our series of pilocytic astrocytomas, 18 patients harbored progressive lesions located in the brainstem. Tumor control was achieved after radiosurgery in 10 patients (56%). No patient with a brainstem lesion experienced any procedure-related morbidity or mortality after stereotactic radiosurgery.
Adjuvant Stereotactic Radiosurgery Compared With Treatment for Recurrence
Tumor control was achieved in 13 (76%) of 17 patients treated using radiosurgery in an adjuvant fashion and in 12 (60%) of 20 patients with recurrent tumors. In the group of patients treated using radiosurgery in the adjuvant setting, the majority (71%) had solid and circumscribed tumors. Nine of these patients harbored tumors in the brainstem. Among patients with recurrent tumors treated with radiosurgery, 65% had solid, circumscribed tumors. Nine of these patients harbored tumors in the brainstem.
Risks of Radiosurgery
The two patients believed to have experienced adverse radiation effects after radiosurgery both displayed improvement in their clinical condition and tumor imaging characteristics 24 and 28 months, respectively, after their procedure.
Biopsy Followed by Stereotactic Radiosurgery
Biopsy followed by radiosurgery of histologically verified pilocytic astrocytoma is a potential treatment alternative in patients with solid, circumscribed tumors who do not undergo surgical resection. In our current series, 11 patients underwent biopsy of tumor and subsequent radiosurgery. Tumor control was achieved in 82% of patients. The majority (73%) of the lesions were solid and circumscribed.
Stereotactic Cyst Aspiration
Attainment of tumor cyst control by using stereotactic radiosurgery alone is unusual and other means to control cyst growth must be used. Stereotactic cyst aspiration is a low-risk procedure that can be used as an adjunct to (prior to) radiosurgery to reduce target volume specifically for cystic tumors in critical brain locations. The combination of cyst aspiration and radiosurgery is effective for symptom improvement as well as for prevention of cyst recurrence. In a study by Niranjan, et al., 26 six patients with deeply seated pilocytic astrocytomas underwent stereotactic cyst aspiration following fractionated radiation therapy. Three of these patients underwent radiosurgery after stereotactic cyst aspiration (same patients included in this series) to capitalize on reduced tumor volume. All six patients displayed symptomatic improvement after cyst aspiration and remain alive.
Prognostic Factors
Patients with multifocal pilocytic tumors had a worse prognosis in this series. Patients in whom previous fractionated radiation therapy failed also had a worse prognosis after radiosurgery. These patients required multiple therapies in addition to radiosurgery and fractionated radiation therapy for control of their tumor. Older patients and those in whom less than 15 Gy was delivered to the tumor margin had poorer outcomes in this series (Fig. 4) .
Conclusions
The use of stereotactic radiosurgery as part of multimodal therapy for progressive, recurrent, or unresectable pilocytic astrocytomas is a safe and promising therapeutic modality. It may replace fractionated radiation therapy and chemotherapy in selected patients.
